Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring <3 cm

Histopathology

Volumn 66, Issue 5, 2015, Pages 732-739

  Takagi, Yuzo ^a   Matsuoka, Yuki ^a   Shiomi, Tatsushi ^a   Nosaka, Kanae ^a   Takeda, Chikako ^a   Haruki, Tomohiro ^a   Araki, Kunio ^a   Taniguchi, Yuji ^a   Nakamura, Hiroshige ^a   Umekita, Yoshihisa ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Lung adenocarcinoma; Maspin; Micropapillary; Prognosis

Indexed keywords

MASPIN; SERINE PROTEINASE INHIBITOR; SERPIN-B5;

AGED; ARTICLE; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; CANCER STAGING; CYTOPLASM; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS;

ADENOCARCINOMA; AGED; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 84924571652     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12586     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Parkin M, Tyczynski JE, Boffetta P et al. Lung cancer epidemiology and etiology. In Travis WD, Blambilla E, Muller-Hermelink HK eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004; 12-15.
3. Travis WD, Brambilla E, Noguchi M et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011; 6; 244-285.
4. Asamura H, Goya T, Koshiishi Y et al. A Japanese lung cancer registry study: prognosis of 13, 010 resected lung cancers. J. Thorac. Oncol. 2008; 3; 46-52.
5. Kelsey CR, Higgins KA, Peterson BL et al. Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. J. Thorac. Cardiovasc. Surg. 2013; 146; 768-773.
6. Zou Z, Anisowicz A, Hendrix MJ et al. Maspin, a serpin with tumour-suppressant activity in human mammary epithelial cells. Science 1994; 263; 526-529.
7. Bodenstine TM, Seftor RE, Khalkhali-Ellis Z et al. Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev. 2012; 31; 529-551.
8. Umekita Y, Ohi Y, Sagara Y et al. Expression of maspin predicts poor prognosis in breast cancer patients. Int. J. Cancer 2002; 100; 452-455.
9. Umekita Y, Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003; 42; 541-545.
10. Umekita Y, Ohi Y, Souda M et al. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer. Diagn. Pathol. 2011; 6; 36.
11. Umekita Y, Souda M, Yoshida H. Expression of maspin in colorectal cancer. In Vivo 2006; 13; 317-321.
12. Tsuji T, Umekita Y, Ohi Y et al. Maspin expression is up-regulated during the progression of endometrioid endometrial carcinoma. Histopathology 2007; 51; 871-874.
13. Tsuji T, Togami S, Douchi T et al. Difference in subcellular localization of maspin expression in ovarian mucinous borderline tumour. Histopathology 2009; 55; 130-132.
14. Nakagawa M, Katakura H, Adachi M et al. Maspin expression and its clinical significance in nonsmall cell lung cancer. Ann. Surg. Oncol. 2006; 13; 1517-1523.
15. Takanami I, Abiko T, Koizumi S. Expression of maspin in non-small-cell lung cancer: correlation with clinical features. Clin. Lung Cancer 2008; 9; 361-366.
16. Frey A, Soubani AO, Adam AK et al. Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology 2009; 54; 590-597.
17. Hirai K, Koizumi K, Haraguchi S et al. Prognostic significance of the tumour suppressor gene maspin in non-small cell lung cancer. Ann. Thorac. Surg. 2005; 79; 248-253.
18. Lonardo F, Li X, Siddiq F et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006; 51; 31-39.
19. Woenckhaus M, Bubendorf L, Dalquen P et al. Nuclear and cytoplasmic maspin expression in primary non-small cell lung cancer. J. Clin. Pathol. 2007; 60; 483-486.
20. Miyoshi T, Satoh Y, Okumura S et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am. J. Surg. Pathol. 2003; 27; 101-109.
21. Yoshizawa A, Motoi N, Riely GJ et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for future revision of staging based on analysis of 514 stage I cases. Mod. Pathol. 2011; 24; 653-664.
22. Sanchez-Mora N, Presmanes MC, Monroy V et al. Micropapillary lung adenocarcinoma: a distinctive histological subtype with prognostic significance. Case series. Hum. Pathol. 2008; 39; 324-330.
23. Goulet B, Kennette W, Ablack A et al. Nuclear localization of maspin is essential for its inhibition of tumour growth and metastasis. Lab. Invest. 2011; 91; 1181-1187.
24. Kamiya K, Hayashi Y, Douguchi J et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod. Pathol. 2008; 21; 992-1001.
25. Endsley MP, Hu Y, Deng Y et al. Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion. J. Biol. Chem. 2011; 286; 24599-24607.
26. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006; 66; 4795-4801.